This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Anavex Life Sciences Corp.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Mohammad Michel Afshar: Innovator in Sigma-1 Receptor Therapy
Introduction
Mohammad Michel Afshar is a prominent inventor based in Paris, France. He has made significant contributions to the field of medical science, particularly in the area of Sigma-1 receptor therapy. His innovative approach aims to personalize treatment for patients suffering from neurodevelopmental and neurodegenerative diseases.
Latest Patents
Afshar holds a patent titled "Optimized sigma-1 agonist method of responder selection and treatment." This patent provides insights into genetic polymorphisms that are associated with altered responses to Sigma-1 receptor therapy. The disclosure emphasizes the importance of these polymorphisms in personalizing treatment for individuals in need of Sigma-1 receptor therapy.
Career Highlights
Afshar is currently associated with Anavex Life Sciences Corporation, where he continues to advance research in the field of Sigma-1 receptor therapy. His work is pivotal in developing targeted therapies that can improve patient outcomes.
Collaborations
Some of his notable coworkers include Christopher U Missling and Frédéric Parmentier, who collaborate with him in various research initiatives aimed at enhancing the efficacy of Sigma-1 receptor therapies.
Conclusion
Mohammad Michel Afshar's contributions to the field of Sigma-1 receptor therapy highlight his commitment to improving treatment options for patients with complex neurological conditions. His innovative work continues to pave the way for advancements in personalized medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile